Advertisement

Topics

Study looks at interchangeability between adalimumab biosimilar candidate and Humira

16:42 EDT 28 Jul 2017 | Healio

Boehringer Ingelheim announced that patient enrollment has begun for its study to demonstrate that BI 695501, its adalimumab biosimilar candidate, is interchangeable with the U.S.-marketed formulation of Humira 40 mg/0.8 mL.The pharmacokinetics and clinical outcomes will be compared between patients with moderate-to-severe chronic plaque psoriasis receiving Humira (adalimumab, AbbVie) continuously and those who switch repeatedly between adalimumab and BI 695501, according to a news release. Safety, immunogenicity and efficacy also will be measured in the study.

Original Article: Study looks at interchangeability between adalimumab biosimilar candidate and Humira

NEXT ARTICLE

More From BioPortfolio on "Study looks at interchangeability between adalimumab biosimilar candidate and Humira"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...